Strategy, commercialization, and investment support for rare disease

Led by a team of seasoned biopharmaceutical executives, operators, and investors

Find out More

Initial Partnership

RareGen partnered with Sandoz to launch the first-to-file generic of Treprostinil Injection for the treatment of patients with Pulmonary Arterial Hypertension (PAH). RareGen has hired an experienced, national salesforce in PAH.
Contact Us

Contact Us

If you have business development ideas, are looking for an investor for a commercial-ready or late stage clinical asset, or are looking for a commercial partner, please get in touch.

All Materials Copyright RareGen
Durham, NC

Back to Top